ES2284858T3 - Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina. - Google Patents

Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina. Download PDF

Info

Publication number
ES2284858T3
ES2284858T3 ES02724904T ES02724904T ES2284858T3 ES 2284858 T3 ES2284858 T3 ES 2284858T3 ES 02724904 T ES02724904 T ES 02724904T ES 02724904 T ES02724904 T ES 02724904T ES 2284858 T3 ES2284858 T3 ES 2284858T3
Authority
ES
Spain
Prior art keywords
disease
neurological
erythropoietin
use according
psychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02724904T
Other languages
English (en)
Spanish (es)
Inventor
Carlos Plata Salaman
Virginia Smith-Swintosky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of ES2284858T3 publication Critical patent/ES2284858T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
ES02724904T 2001-02-02 2002-01-24 Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina. Expired - Lifetime ES2284858T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26619401P 2001-02-02 2001-02-02
US266194P 2001-02-02

Publications (1)

Publication Number Publication Date
ES2284858T3 true ES2284858T3 (es) 2007-11-16

Family

ID=23013568

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02724904T Expired - Lifetime ES2284858T3 (es) 2001-02-02 2002-01-24 Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.

Country Status (17)

Country Link
US (2) US6908902B2 (enExample)
EP (1) EP1471871B1 (enExample)
JP (1) JP2005501801A (enExample)
KR (1) KR100896971B1 (enExample)
AT (1) ATE361089T1 (enExample)
CA (1) CA2437333A1 (enExample)
CY (1) CY1106733T1 (enExample)
DE (1) DE60219961T8 (enExample)
DK (1) DK1471871T3 (enExample)
ES (1) ES2284858T3 (enExample)
MX (1) MXPA03006952A (enExample)
NO (1) NO20033440L (enExample)
NZ (1) NZ548578A (enExample)
PT (1) PT1471871E (enExample)
RU (1) RU2317086C2 (enExample)
WO (1) WO2002064085A2 (enExample)
ZA (1) ZA200306818B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
KR100896971B1 (ko) * 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법
US20030060423A1 (en) * 2001-08-30 2003-03-27 Plata-Salaman Carlos R. Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
EP1815854A1 (en) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Treatment of dyskenesia
ES2286453T3 (es) * 2002-09-17 2007-12-01 Motac Neuroscience Limited Tratamiento de la discinesia.
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2007020922A1 (ja) * 2005-08-17 2007-02-22 Chugai Seiyaku Kabushiki Kaisha 脳疾患の治療剤および予防剤
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2008022349A2 (en) * 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
WO2008088820A2 (en) * 2007-01-16 2008-07-24 The Johns Hopkins University Glutamate receptor antagonists and methods of use
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
RU2335296C1 (ru) * 2007-06-26 2008-10-10 Сергей Марович Дудкин Фармацевтическая композиция для профилактики и лечения неврологических заболеваний
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
CA2724841A1 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
US9457008B2 (en) 2012-03-23 2016-10-04 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Joint product comprising synephrine and topiramate
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
JPH09501418A (ja) 1993-07-19 1997-02-10 アムジエン・インコーポレーテツド エアゾル化タンパク質の安定化
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
DE69434652T2 (de) * 1993-12-23 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive pseudofructopyranose sulfamate
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
DE69736780T2 (de) 1996-08-02 2007-09-06 Ortho-Mcneil Pharmaceutical, Inc. Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer
ATE341625T1 (de) 1997-07-23 2006-10-15 Roche Diagnostics Gmbh Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
PT902085E (pt) 1997-09-01 2004-02-27 Aventis Pharma Gmbh Eritropoietina humana recombinante com perfil de glicosilacao vantajoso
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
AU759467B2 (en) * 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AU775422B2 (en) 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
JP2003521471A (ja) * 1999-04-08 2003-07-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体
PL352223A1 (en) * 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
CA2270795A1 (en) * 1999-05-05 2000-11-05 Gestilab Inc. Neuroprotective compositions and uses thereof
KR100896971B1 (ko) * 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법

Also Published As

Publication number Publication date
WO2002064085A3 (en) 2004-09-10
DE60219961T2 (de) 2008-01-17
CA2437333A1 (en) 2002-08-22
KR100896971B1 (ko) 2009-05-14
CY1106733T1 (el) 2012-05-23
KR20040011458A (ko) 2004-02-05
JP2005501801A (ja) 2005-01-20
RU2003124059A (ru) 2005-01-27
ZA200306818B (en) 2005-02-23
DE60219961T8 (de) 2008-04-17
EP1471871B1 (en) 2007-05-02
NZ548578A (en) 2008-03-28
EP1471871A4 (en) 2005-11-09
PT1471871E (pt) 2007-06-05
US6908902B2 (en) 2005-06-21
DE60219961D1 (de) 2007-06-14
RU2317086C2 (ru) 2008-02-20
ATE361089T1 (de) 2007-05-15
NO20033440L (no) 2003-09-29
MXPA03006952A (es) 2004-10-15
EP1471871A2 (en) 2004-11-03
DK1471871T3 (da) 2007-09-17
US20020169109A1 (en) 2002-11-14
WO2002064085A2 (en) 2002-08-22
NO20033440D0 (no) 2003-08-01
US20050261182A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
ES2284858T3 (es) Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
CN106232612B (zh) 骨选择性成骨性氧固醇双膦酸盐类似物
US6776984B1 (en) Induced regeneration and repair of damaged neurons and nerve axon myelin
ES2333399T3 (es) Metodos para tratar una leucemia.
JP6173298B2 (ja) 治療薬としての肝細胞増殖因子模倣体
RU2707191C2 (ru) Нейродегенеративные расстройства
JP2003534384A (ja) 神経保護性ペプチド
ES2656353T3 (es) Nuevas aplicaciones de HIP/PAP o derivados de la misma
EP3197482A1 (en) Methods of treating traumatic brain injury
KR20030076714A (ko) 신경퇴행성 질환을 예방하거나 치료하는데 사용하기 위한카바메이트 화합물
WO2002099081A2 (en) Methods of using colony stimulating factors in the treatment of tissue damage and ischemia
EP3337811B1 (en) Positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases
AU2002255504B2 (en) Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
AU2002255504A1 (en) Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR20220003652A (ko) 에리스로포이에틴-유래된 펩타이드, 이의 제조 방법 및 이의 용도
Johnstone The Influence of Neurotrophins on Traumatic Brain Injury, Fracture Healing and Bone Metabolism
EP1210103B1 (en) Thrombopoietin for treatment of neurologic damage
AU2003200309B2 (en) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
WO2007020672A2 (en) Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
CN1278736C (zh) 一个新的多巴胺能神经元保护因子及其应用
HK1260703A1 (en) Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
WO2012137645A1 (ja) 抗癌剤に起因する異痛症の予防及び／又は治療剤
WO1994009807A1 (en) Pharmaceutical preparations containing neurotrophic factors and gangliosides for treating nervous system pathologies